Back D - Search Results

1

The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.

Vera JH, Jackson A, Dickinson L, Else L, Barber T, Mora-Peris B, Back D, Boffito M, Winston A. Vera JH, et al. Among authors: back d. HIV Clin Trials. 2015 Jan-Feb;16(1):39-42. doi: 10.1179/1528433614Z.0000000006. Epub 2015 Jan 14. HIV Clin Trials. 2015. PMID: 25777188

2

Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.

Jackson A, Else L, Higgs C, Karolia Z, Khoo S, Back D, Devitt E, Pozniak A, Boffito M. Jackson A, et al. Among authors: back d. HIV Clin Trials. 2018 Feb;19(1):31-37. doi: 10.1080/15284336.2017.1408928. Epub 2017 Nov 30. HIV Clin Trials. 2018. PMID: 29189101

3

Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

Jackson A, Moyle G, Dickinson L, Back D, Khoo S, Taylor J, Gedela K, Abongomera G, Gazzard B, Boffito M. Jackson A, et al. Among authors: back d. Antivir Ther. 2012;17(1):19-24. doi: 10.3851/IMP1910. Antivir Ther. 2012. PMID: 22267465 Free PMC article. Clinical Trial.

4

Alterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopy.

Vera JH, Garvey LJ, Allsop JM, Kaye S, McClure MO, Back D, Taylor-Robinson SD, Winston A. Vera JH, et al. Among authors: back d. HIV Clin Trials. 2012 Jul-Aug;13(4):222-7. doi: 10.1310/hct1304-222. HIV Clin Trials. 2012. PMID: 22849963

5

Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.

Mora-Peris B, Croucher A, Else LJ, Vera JH, Khoo S, Scullard G, Back D, Winston A. Mora-Peris B, et al. Among authors: back d. J Antimicrob Chemother. 2013 Jun;68(6):1348-53. doi: 10.1093/jac/dkt006. Epub 2013 Jan 30. J Antimicrob Chemother. 2013. PMID: 23364475

6

Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.

Mora-Peris B, Watson V, Vera JH, Weston R, Waldman AD, Kaye S, Khoo S, Mackie NE, Back D, Winston A. Mora-Peris B, et al. Among authors: back d. J Antimicrob Chemother. 2014 Jun;69(6):1642-7. doi: 10.1093/jac/dku018. Epub 2014 Feb 11. J Antimicrob Chemother. 2014. PMID: 24521854

7

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.

Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R. Dickinson L, et al. Among authors: back d. Clin Pharmacokinet. 2016 Jul;55(7):861-873. doi: 10.1007/s40262-015-0360-5. Clin Pharmacokinet. 2016. PMID: 26715213 Free PMC article. Clinical Trial.

8

The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

Garvey L, Latch N, Erlwein OW, Mackie NE, Walsh J, Scullard G, McClure MO, Dickinson L, Back D, Winston A. Garvey L, et al. Among authors: back d. Antivir Ther. 2010;15(2):213-8. doi: 10.3851/IMP1517. Antivir Ther. 2010. PMID: 20386076 Clinical Trial.

9

Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.

Jackson A, D'Avolio A, Watson V, Bonora S, Back D, Taylor J, Armenis K, Gazzard B, Moyle G, Boffito M. Jackson A, et al. Among authors: d avolio a, back d. J Antimicrob Chemother. 2011 Apr;66(4):885-9. doi: 10.1093/jac/dkq546. Epub 2011 Jan 22. J Antimicrob Chemother. 2011. PMID: 21393207 Clinical Trial.

10

Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.

Jackson A, Watson V, Back D, Khoo S, Liptrott N, Egan D, Gedela K, Higgs C, Abbas R, Gazzard B, Boffito M. Jackson A, et al. Among authors: back d. J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):450-7. doi: 10.1097/QAI.0b013e3182364c67. J Acquir Immune Defic Syndr. 2011. PMID: 21926632 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

815 results

Search Page

Filters